Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
patent expirations
Fierce Biotech
China biotechs ‘reshaping’ US biopharma: Jefferies report
In 2025's Q1, 32% of outlicensing biotech deal value occurred in China versus 21% reported in both 2024 and 2023, according to Jefferies.
Gabrielle Masson
Jul 14, 2025 2:30pm
JPM25: Takeda touts 6 pipeline assets with big sales potential
Jan 15, 2025 3:17pm
Teva hit with €463M fine over Copaxone misconduct claims in EU
Oct 31, 2024 10:45am
'The Top Line': 2023's exclusivity losses, this week's news
Apr 7, 2023 7:30am
The top 10 drug patent expirations of 2023
Mar 13, 2023 3:00am
The top 20 drugs by 2021 sales
May 31, 2022 3:00am
